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Abstract
Background: Numerous linkage studies have been performed in pedigrees of Autism Spectrum Disorders, and these studies
point to diverse loci and etiologies of autism in different pedigrees. The underlying pattern may be identified by an
integrative approach, especially since ASD is a complex disorder manifested through many loci.
Method: Autism spectrum disorder (ASD) was studied through two different and independent genome-scale measurement
modalities. We analyzed the results of copy number variation in autism and triangulated these with linkage studies.
Results: Consistently across both genome-scale measurements, the same two molecular themes emerged: immune/
chemokine pathways and developmental pathways.
Conclusion: Linkage studies in aggregate do indeed share a thematic consistency, one which structural analyses
recapitulate with high significance. These results also show for the first time that genomic profiling of pathways using a
recombination distance metric can capture pathways that are consistent with those obtained from copy number variations
(CNV).
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Introduction
Autism spectrum disorder, a neurodevelopmental disease with
an incidence of up to 1% is increasingly recognized as a highly
heterogeneous complex disorder [1], [2], [3], [4]. Genetic studies
via pedigree analysis and via studying the disruptions at the
nucleotide level (such as copy number variations (CNVs) or
structural variations (SVs)) have been quite successful in the study
of various disorders, especially in single gene or Mendelian
disorders.
In Mendelian disorders, such as for example, Huntington’s
disease, various pedigree analyses that are conducted on different
families point with remarkable consistency to the same locus.
However, the results of numerous pedigree analyses in autism have
mapped to different genetic loci, possibly a reflection of the non-
Mendelian and complex nature of autism. Single gene approaches
may fail to find underlying mechanisms in this context where an
integrative approach might succeed. Moreover although there is
considerable clinical heterogeneity in autism (a now prototypical
spectrum disorder), there is considerable concordance ([5], [6])
amongst expert developmental specialists by the time the affected
child is five years old or older. Therefore, we hypothesized that
even if autism has complex etiologies, it does have an underlying
molecular physiology overlap shared by autistic individuals. This
overlap may occur at several levels (ranging from clinical
symptoms to gene expression). Because biological pathways take
direct account of mechanistic principles underlying biological
function, we therefore focused on biological pathways as our level
of abstraction for finding this overlap.
From this perspective an affected individual from an autism
pedigree (which is used to obtain linkage peaks in autism) may
point to a certain gene (and thus a particular location on the
genome) within a common pathway perturbed in autism. Another
pedigree may point to a different location within the same
pathway. The same may be true of structural perturbations in the
genome (Copy Number Variations (CNVs) or Structural Varia-
tions) with each affected individual’s CNVs capturing different
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aspects of the same common pathway. Figure 1 illustrates this
concept and the idea is captured in a methodology called Linkage
ordered Gene Sets (LoGS) that we present in this paper.
LoGS takes pre-existing gene sets and ranks them in terms of
their importance in autism. To integrate CNV studies with LoGS,
we first looked for pathways that were perturbed in CNVs of
autistic individuals (Table S1). The top two ranked pathways from
the CNV analysis were both immune function related. With these
top ranked pathways we identified three other immune related
pathways located in the top 20 sets from the CNV analysis and
aggregated these into 5 new gene sets (individually referred to as
iCNV-a through e and collectively as iCNV-5 for immune CNV 5
sets). These iCNV-5 gene sets along with 186 other a priori created
gene sets were then tested in LoGS as summarized in Figure 2.
LoGS is based on the idea that various loci obtained from
pedigree studies can be used to rank previously compiled pathways
important in that disease. This ranking is obtained through a
ranking of all genes linked to that locus using genetic distance
(within different sized linkage windows). Consider two markers
that have been identified in two pedigree studies, one on
chromosome 1 and another located on chromosome 7. We first
find all genes within a 50 cM window on either side of the marker
on chromosome 1 and repeat again for the marker on
chromosome 7. We then combine the markers such that they
both sit at the origin (see Figure 3) and then rank all genes within
50 cM of these two markers in terms of their distance from this
combined origin. Since distances to the left of the combined origin
are equivalent to distances to the right (we are only interested in
the distances of the genes from this common origin), we rotate the
left hand genes from the origin into the right hand side (or take the
absolute value). This is shown in Figure 4 (see methods section for
details). 50 cM windows on either side of the loci are chosen
because that is the limit of linkage and because choosing this
window size allows the largest number of genes that may be
responsible.
Researchers typically take a marker and use the closest gene to
that marker as an important gene in that disease. Our rationale for
using all genes within a certain sized window rather than the
closest flanking genes is based upon the following ideas:
1. Both flanking and some non flanking genes next to the locus
may be important.
2. The locus itself may be important. However, its importance
may influence genes that are not the closest to it. A disruption
can occur in the genome that may influence non flanking genes
[7], [8], [9]. For example, according to Kleinjan ‘‘A complex
hotspot for limb abnormalities is found 1 Mb upstream of
SHH, within the introns of LMBR1. The region contains a
Figure 1. A conceptual picture of our overall analysis. Each affected individual from different pedigrees captures a different part of the same
pathway. The same will be true of different CNVs in different autistic individuals.
doi:10.1371/journal.pone.0048835.g001
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conserved noncoding element that is capable of functioning as
an enhancer that drives SHH expression in the limb bud in
both an anterior and posterior zone, as well as a repressor
element that silences the anterior expression. The Sasquatch
insertion disrupts the anterior repression function, whereas the
acheiropodia deletion is thought to disrupt positive enhancer
activity.’’ Another gene RNF32 sits between the region of
control and the SHH gene that is controlled [7]. Further,
Introns can contain microsatellites [10], [11]. Please see
Figure 5A (this figure is adapted from [7]).
3. Even if the closest gene(s) to the locus is (are) the most
important, we just don’t have the exact location of the locus.
There may be uncertainty of 15 cM on either side of the locus
[12]. As shown in Figure 5B in the absence of further
information, we place the measured marker at the center of the
region of uncertainty and therefore consider genes not merely
adjacent.
4. Microsatellite marker density in pedigree analysis is low and
consequently the signal for the correct location affecting the
disease may arise at a distance from the marker. For example,
Yonan et al.’s study [13] of autism susceptibility loci used 408
markers. Since a conservative estimate for the number of genes
on the human genome is approximately 20,000 genes, (which
on average are 10–15 Kb [14]), and thus microsatellite
markers on average are spaced 50 genes apart. Therefore the
closest gene to the marker may not be the gene with the
etiological variant (Figure 5C). It is worth noting that similar
considerations at a different scale occur with much higher
density markers more typical of GWAS [15].
Using LoGS, we show that integrated results of linkage studies
are highly congruent with those obtained from copy number
variation profiles of individuals with autism as compared with
those of controls. This congruence points to a common set of
Figure 2. Overall analysis scheme. All genes within CNVs were used to find the top ranked pathways in the CNVs (A) and these new pathways
along with other a priori created pathways were tested using LoGS (B).
doi:10.1371/journal.pone.0048835.g002
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pathways previously implicated in immunological response,
inflammation, and development. Moreover, the top 2 ranked
gene sets in CNVs ranked within the top 4 LoGS sets, and the
iCNV-5 gene sets claimed the top 4 ranks (as well as rank 17) in
LoGS.
Results
Structural variations in autism
The group of genes that reside wholly within structural variation
regions were found to be enriched (using the EASE [16] Gene
Ontology enrichment program) for 5 sets implicated in immune
processes (Table S2). The results of EASE enrichment over CNV
genes are shown in Table S1 where we present the 20 top enriched
categories. These gene sets obtained ranks 1, 2, 10, 17, and 19),
and are heretofore referred to as iCNV-5 (iCNV-a through e)—
the Bonferroni corrected p-values for the 2 top ranked sets (both
pertaining to immune function) are 261024 and 1.761024.
To gain further insights into the CNV based immune function
gene sets that were generated, we took all the genes within the
iCNV-5 gene sets and reviewed the primary CNV data to see if
there was copy number gain or loss (Table 1). All the chemokines
show a copy number gain while all the interferons show a loss.
Interestingly, ethanol oxidation, ethanol metabolism, and alcohol
dehydrogenase activity feature prominently in the CNV analysis
(scoring at ranks 4, 5 and 14 respectively).
Gene sets relating to immune function and development
score highly in LoGS
When LoGS was run over a set of linkage studies (for 6905
genes within 50 cM of at least one of the linkage peaks) we found
that iCNV-5 was highly ranked by LoGS (Table 2). When we
restricted LoGS to only those genes that were in CNV’s and that
Figure 3. General overview of LoGS. We pick markers on various chromosome implicated in autism. We then find genes within 50 cM of each
marker. Next we ‘align’ each marker to have the same or common origin and then rank genes from this common origin.
doi:10.1371/journal.pone.0048835.g003
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were within 50% recombination distance of the linkage peaks, we
were left with 319 genes. LoGS ranked the gene sets as shown in
Table S3. The five immunological and inflammation gene sets
(iCNV-5) again ranked topmost. Following the iCNV-5 immune
gene sets, pathways enriched for development (c6 gene set) and
neurogenesis (c34 gene set) score highly. Pathways labeled, by the
GSEA developers [17], as c6 and c34 were the fifth- and sixth-
most highly ranked, respectively. The gene memberships from
these two sets were then analyzed with EASE [18] to find Gene
Ontology categories enriched in each of these gene sets. The c6
gene set was enriched for epidermal differentiation and ectoderm
development and the c34 gene set was overrepresented with genes
annotated as involved in ‘neurogenesis’ and ‘hydrolase activity,
acting on acid anhydrides’. Tables S4 and S5 list the gene
memberships of these two gene sets and their top enriched
categories as determined by EASE.
Significance Determination
To determine the statistical significance of the results of the
LoGS analysis, a permutation test was adopted. The ranks of the
genes that are within the 50 cM recombination distance of the
linkage peaks that were used in our analysis were permuted and
then tested for the top ranked gene sets in 1000 runs. The p value
was then computed as the number of times a particular gene set
obtained top rank in the 1000 runs divided by 1000. We note that
all the gene sets tested show significance at the 0.05 level (Table 2).
Effect of linkage window size
Because 50 cM is a relatively large distance over which to study
the effects of linkage from a locus, we took different distances from
the loci to see how sensitive our results are to the size of our
window. We tested five smaller windows: 40 cM, 30 cM, 20 cM,
10 cM, and 5 cM. These results are presented in Table S6. We
note that shrinking the distance around the loci down to 5 cM
from 50 cM substantially preserves the results.
LoGS without LOD score normalization
Next we tested how sensitive our analysis is to the LOD score
normalization that is used as one step in our LoGS analysis by
removing this normalization. Our strategy for the LoGS analysis
started by taking a cutoff threshold of 3 for the LOD score for any
linkage peak to be part of our analysis. Since this is a highly
significant LOD score, relatively few studies were expected to
surpass this LOD score substantially. Further, most of the LOD
scores of studies that were above 3 were close to this number.
Thus, we expected our results to remain substantially the same
when the LOD score normalization was removed from our study.
The results of running the LoGS without the LOD score
normalization are presented in Table S7, and we see that in fact
our results remain essentially the same.
Discussion
With two different genome analyses, LoGS and CNV, immune
system and developmental pathways appear to be involved in
autism. These data are remarkably consistent. The linkage loci
used in LoGS were compiled from diverse sources spanning over a
decade. The CNV studies were performed recently by a different
set of investigators with a study population of minimal overlap
with the subjects in the linkage studies. In LoGS, the top ranked
gene sets (iCNV-5) were those obtained from the CNV analyses.
After iCNV-5, the next highest gene sets related to development
(organogenesis and neurogenesis). Further, not only were 4 of the
new gene sets (iCNV-5) at the very top of the LoGS analysis, but
the developmental theme obtained using LoGS was recapitulated
in the CNV analysis with developmental themes at ranks 3, 6, 12,
13, and 18 in the top 20 over-represented pathways. In toto these
results coherently point to functional and genomic differences in
autism related to immune function as well as development.
Prior work as reviewed in [19] has implicated immune function
in autism histologically in brain and blood, in the expression of
proteins in brain and blood, and in several epidemiological studies.
Vargas et al. used immunohistochemistry, cytokine protein arrays,
as well as enzyme linked immunosorbent assays in postmortem
brain samples of autistic individuals and found significant
activation of microglia, astroglia, and neuroglia in the cerebral
cortex, white matter as well as the cerebellum [20]. Others have
expression profiled with DNA microarrays using post mortem
brain tissue from autistics reporting that ‘‘Overall, these expression
patterns appear to be more associated with the late recovery phase
of autoimmune brain disorders, than with the innate immune
response characteristic of neurodegenerative diseases’’ [21].
Peripheral blood transcriptional profiling in autistic children (not
suffering from other disorders such as fragile X mental retardation)
showed increased expression of Natural killer cell receptors and
effector molecules [22]. Proteomic profiling of blood serum from
autistic children showed an increase in complement proteins [23].
In utero infections have been reported to predispose the
growing fetus to developing autism and schizophrenia [24] with
infections during the earlier parts of pregnancy showing progres-
sively more severe phenotypes. Respiratory infections as well as
infections with Rubella during pregnancy may predispose the
growing fetus to developing schizophrenia [25]. Mouse models of
autism further strongly suggest a role for the immune system in
autism. Ponzio et al showed ‘‘immune mechanisms, in general,
and cytokine dysregulation, in particular, as contributing factors in
their [autism spectrum disorder] etiology’’ [26]. It is also becoming
increasingly clear that the same ligands and receptors employed by
the immune system play a role in the development of the central
nervous system and in its functioning in the mature brain [27],
Figure 4. Genes to the left and right of the marker are treated
equally (LoGS overview continued). Here we show how left ranked
genes and right ranked genes are placed together in the same ranking.
doi:10.1371/journal.pone.0048835.g004
Disordered Neuro_Immune Function in Autism
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e48835
[28], [29]. This raises the question of whether the immune/
inflammatory signature we have found across the two genomic
measurement modalities in ASD is part and parcel of the
developmental disorder, a consequence of that disorder, or its
trigger.
Nonetheless, it is striking that of the genes implicated by LoGS,
there is a loss of genomic copies in the interferon alphas (IFNA10,
IFNA14, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA8,
IFNA17) and gain of copies in the ‘‘C-C’’ motif chemokine
ligands (CCL1, CCL11, CCL13, CCL2, CCL7, CCL8) as
summarized in Table 1. Several of these chemokines have been
found to be overexpressed in inflammatory diseases such as
ulcerative colitis [30], atopic dermatitis [31], rheumatoid arthritis
[32], and in neurocognitive disorders [33]. This suggests an
etiological basis for the disordered innate immunity response
found in autism [34], particularly as mediated by monocytes [35]
and the histologically related microglia [20], [36], [37]. The loss of
interferon alpha copies, usually implicated in the response to viral
infection and another component of innate immunity, could also
account for a dysregulated, secondary or compensatory response
of interferons and chemokines. Several of these messengers ‘‘…are
produced by neurons and glia in the adult brain, and that they can
acutely influence synaptic transmission.’’ [38]. Certain neurotro-
phins (which are also released by immune cells [39] cause activity-
dependent changes in neural circuits in development [38].
The above could be suggestive of a link between in utero
infections and brain development in the child. Thus, the genetic
background by itself would not be enough via this view to cause a
deranged developmental process which would rather only occur in
the presence of relevant infections. Interferons are important in
Figure 5. Why the closest gene is not necessarily the best gene. A. Far away genes can be influenced by genes closer to a marker. Thus, we
can’t just use the closest genes to the marker. B. Since our real locus could be anywhere within the 30 cM window, any of the genes within the
window could be the closest gene, and since our best location for the marker is the center of the window, we simply rank the genes from this point
to take into account the fact that any of the genes within the window could be the gene closest to some ‘real’ marker. C. The low density of markers
means that many genes are ‘covered’ by each marker. The gene of interest may be far from the marker and may not necessarily be the closest gene
from the marker.
doi:10.1371/journal.pone.0048835.g005
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the control of viral infections via the induced expression of
interferon-stimulated genes [40]. The loss of copy number in the
interferon genes suggests a possible reduced expression of such
genes when stimulated. Thus, a viral infection would last longer
under such a genetic background. Viral infections also lead to the
expression of various chemokines in the CNS [41]. Further,
chemokines are also involved in brain development [27], [41].
There would therefore be a longer generation of chemokines and
other cytokines that could interfere with normal brain develop-
ment. Further, gain in copy number in chemokines may lead to
higher levels of these chemokines and would thus exacerbate the
derangement in brain development.
LoGS is agnostic to the type of marker used in the analysis
(microsatellites, SNPs etc). SNPs could be exclusively used from
GWAS studies [42]. However, the success of this method will be
highly dependent on the nature of the original studies. Given that
the majority of the more recent SNP population investigations are
association rather than linkage studies, the efficacy of LoGS in
these settings will depend on the distributional and ‘‘penetrance’’
characteristics of the genomic variants across the spectrum of
autism. These characteristics remain to be determined. Others
have tried to intersect data and findings. For example, Raychaud-
huri describes a method to find the most important locus or gene
from various loci obtained in a disease [43] while Hannum looks
for clusters of genes relevant in a disease [44]. While these are both
interesting studies, neither looks for functionally important
pathways that could be relevant to a disease as does LoGS.
The results presented in this paper show that immune function
may play a critical role in the genesis, development, or
manifestation of autism.
Methods
Linkage Ordered Gene Sets
In linkage studies, the closer a gene is to a locus associated with
a disorder the more likely it is to be involved in the disorder. The
commonly used genetic distance measures the distance as a
function of recombination events. In LoGS, all the linked genes
(,50% recombination) on the chromosome with the marker are
ranked as a linear function of genetic distance from the marker.
However, each marker has a particular probabilistic relationship
with the trait/disease being studied often quantified by a LOD
score. We therefore adjust the rankings of each gene with respect
to a marker by dividing the genetic distance by the LOD score.
We then test a large number of a priori generated gene sets using
this ranking metric to test for non-random distribution of these
gene sets across the ranked list of genes in the manner of Gene Set
Enrichment Analysis [17].
Twenty nine genetic loci implicated in autism in the research
literature with each locus having an LOD score greater than 3
were chosen to be the inputs in the LoGS (Table S8). When there
was more than one LOD score reported in the literature for a
locus (entries 20, 21), the lower score was used to be conservative
with respect to that locus.
By using recombination rates pertaining to each known SNP
location from the Hapmap.org website in combination with the
location of all genes from the ensemble.org website, we were able
to determine the genetic distance of all genes within each of the
chromosomes in Table S8. We searched for SNPs within each
gene. When a gene had more than one SNP, we obtained the
genetic distances of the SNPs towards the two ends of the gene and
these averaged gave us the genetic distance for that gene (when a
gene contained only one SNP, the genetic distance for that SNP
served as the distance for the gene). Genes without SNPs weren’t
used.
To find the location of the autism markers, we obtained the
average location in base units from the range in base units for each
marker. We then found the SNP closest to this average range, and
the genetic distance in recombination units pertaining to that SNP
was then assigned to that marker. Next, each of these distances was
then translated such that the origin was placed at the location of
the marker. This new coordinate system then had genes either at
negative or positive locations vis-a`-vis the particular marker. The
absolute value of each gene’s location was taken and if there were
two or more markers or loci on the same chromosome, we took the
smallest of all the distances of each gene to all the loci (after we had
adjusted for the LOD scores). Further, only genes within 50%
recombination units of any maker were chosen in the study. The
location of each gene was then divided by the LOD score for the
marker used for referencing that gene. All genes from all
chromosomes implicated in the linkage studies were then ranked
using this final metric. This ranked system was then used to obtain
the enrichment score, V, for each gene set tested as outlined
previously [45], [17]. Figure 6 shows this approach for two
chromosomes with 3 markers or loci.
We found the exact location of each of these loci associated with
the disease from the literature. Once we obtained a ranking of all
(linked) genes to all markers, we then took pre-existing gene sets
(which were appropriately filtered to only have the subset of genes
from each gene set that is linked to the markers) and calculated the
Table 1. Copy number gain or loss in the iCNV-5 genes.
Gene symbol Gain/Loss
CCL1 Gain
CCL11 Gain
CCL13 Gain
CCL2 Gain
CCL7 Gain
CCL8 Gain
BMP15 Gain
FAM3C Loss
RNF4 Gain
IFNA10 Loss
IFNA14 Loss
IFNA2 Loss
IFNA21 Loss
IFNA4 Loss
IFNA5 Loss
IFNA6 Loss
IFNA8 Loss
IFNA17 Loss
IFNB1 Loss
IFNW1 Loss
IL11 Loss
TNFSF15 Loss
MX1 Loss
MX2 Loss
doi:10.1371/journal.pone.0048835.t001
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‘enrichment’ score for each gene set along the same lines outlined
previously [45], [17].
A priori gene sets were created as previously reported [46]. The
ranked genes over which we tested these gene sets were the subset
(numbering 6905) of all genes in the genome that fall within 50%
recombination distance of the linkage peak.
Structural variations analysis
We used genome-wide structural variation studies for indepen-
dent selection of common ASD pathways.
Marshall et al [47] have studied the occurrence of structural
variations in autism spectrum disorder. They used 500k SNP chips
to obtain regions showing these variations (described at http://
projects.tcag.ca/autism_500k/). We found all genes that com-
pletely resided within each of these structural variation regions,
and then used EASE [18] to define the molecular themes across
these CNVs. This EASE analysis identified immune related
and developmental pathways (Table S1).
Supporting Information
Table S1 CNV genes in EASE. The top 20 categories in EASE
are shown along with the genes (represented by gene symbols) in
those categories. Shown in order are: gene set; EASE score P
values adjusted for multiple testing; gene symbols.
(DOCX)
Table S2 Immune function gene sets from the copy number
variation (CNV) regions of autistic individuals.
(DOCX)
Table 2. LoGS on autism loci. Shown are the top 20 pathways.
Gene set V P
1 Cytokine activity (iCNV-e) 255 0.005
2 Hematopoietin/IFN-class cytokine receptor binding (iCNV-b) 212 0.007
3 Response to virus (iCNV-c) 174 0.003
4 IFN-a/b receptor binding (iCNV-a) 173 0.002
5 c6: epidermal differentiation (BP), ectoderm development (BP) 168 0.009
6 c34:hydrolase activity (MF), neurogenesis (BP) 126 0.016
7 MAP00960_Alkaloid_biosynthesis_II 119 0
8 OXPHOS_HG-U133A_probes 119 0.01
9 c1:cellular process (BP), cell proliferation (BP) 118 0.011
10 c10:glutathione transferase activity (MF), epidermal differentiation (BP) 116 0.007
11 MAP00531_Glycosaminoglycan_degradation 108 0.007
12 c33 (proteasome complex (CC), synaptic transmission (BP)) 105 0.011
13 MAP00680_Methane_metabolism 103 0.006
14 c28:signal transducer activity (MF), lactose metabolism (BP) 102 0.011
15 MAP00193_ATP_synthesis 101 0.003
16 MAP03070_Type_III_secretion_system 101 0
17 Antiviral response protein activity (iCNV-d) 100 0.005
18 c31:transcription factor activity (MF), cell communication (BP) 100 0.012
19 c3:ribonucleoprotein complex (CC), apoptosis (BP) 99 0.011
20 MAP00190_Oxidative_phosphorylation 97 0.005
Gene sets that begin with ‘c’ are further tested in EASE for their top categories. BP =biological process; CC = cellular component; MF=molecular function.
V = enrichment score for a pathway. P = P value via permutation test.
doi:10.1371/journal.pone.0048835.t002
Figure 6. The rationale behind LoGS. In this figure, we use two loci
to illustrate how LoGS works. Say Chromosome 21 has two loci that
were implicated in ASD while chromosome 9 has just one locus. We
then locate all the genes on chromosomes 1 and 9 and then rank them
by their genetic distance from the closest locus on that chromosome
(for example the gene between loci 1p21.1 and 1q23.3 is closer to
1q23.3 and thus its distance from 1q23.3 is used). This ranking for all
chromosomes (in this example chromosomes 1 and 9) is then collected
and we run gene set enrichment analysis as explained in the methods
section. The black boxes are markers and the dashed lines represent
genes.
doi:10.1371/journal.pone.0048835.g006
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Table S3 Results of LoGS analysis using only genes that were
both within 50% recombination distance of the autism loci AND
overlapped with CNV’s. V= enrichment score.
(DOC)
Table S4 Genes in the c6 and c34 gene sets under the LoGS
analysis.
(DOC)
Table S5 Top Enrichment themes of the c6 and c34 gene sets
using EASE.
(DOCX)
Table S6 LoGS was rerun with different sized windows (forty
percent, thirty percent, twenty percent, ten percent, and 5 percent
recombination units). V= enrichment score.
(DOCX)
Table S7 LoGS without LOD: Except for two gene sets in the
lower part of the top 20 ranking all the other gene sets are
consistent across the LoGS which use the LOD score and the
LoGS without the use of the LOD score. V= enrichment score.
(DOCX)
Table S8 LoGS data input.
(DOCX)
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